Differential subcellular and extracellular localisations of proteins required for insulin-like growth factor- and extracellular matrix-induced signalling events in breast cancer progression

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Plant, Helen C ^a   Kashyap, Abhishek S ^a   Manton, Kerry J ^a   Hollier, Brett G ^a   Hurst, Cameron P ^b   Stein, Sandra R ^c   Francis, Glenn D ^c   Beadle, Geoffrey F ^c   Upton, Zee ^a   Leavesley, David I ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b KHON KAEN UNIVERSITY   (Thailand)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Biomarker; Breast cancer; Extracellular matrix; Insulin like growth factor; Metastasis; Vitronectin

Indexed keywords

BETA1 INTEGRIN; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN AKT1; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 5; STRATIFIN; UNCLASSIFIED DRUG; VITRONECTIN; MAPK1 PROTEIN, HUMAN; SOMATOMEDIN BINDING PROTEIN;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; STROMA; BREAST TUMOR; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY;

BREAST NEOPLASMS; CELL NUCLEUS; CYTOPLASM; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84906829870     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-627     Document Type: Article

References (50)

1. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007, 28(1):20-47. 10.1210/er.2006-0001, 16931767.
2. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008, 12(5):589-603. 10.1517/14728222.12.5.589, 18410242.
3. DeVita V, Hellman S, Rosenburg S. Cancer: Principles & Practice of Oncology 2005, Philadelphia: Lippincott Williams & Wilkins, 7.
4. AIHW, National Breast Cancer Centre & Australasian Association of Cancer Registries Breast Cancer Survival by Size and Nodal Status in Australia 2007, Canberra: AIHW, Breast cancer survival by size and nodal status in Australia, AIHW, National Breast Cancer Centre & Australasian Association of Cancer Registries.
5. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards B. SEER Cancer Statistics Review, 1975-2008 2011, Bethesda, MD: National Cancer Institute.
6. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826. 10.1056/NEJMoa041588, 15591335.
7. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, Van't Veer LJ. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006, 7:278. 10.1186/1471-2164-7-278, 1636049, 17074082.
8. Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology 2003, 144(7):2807-2815. 10.1210/en.2002-221086, 12810534.
9. Hollier BG, Kricker JA, Van Lonkhuyzen DR, Leavesley DI, Upton Z. Substrate-bound insulin-like growth factor (IGF)-I-IGF binding protein-vitronectin-stimulated breast cell migration is enhanced by coactivation of the phosphatidylinositide 3-Kinase/AKT pathway by alphav-integrins and the IGF-I receptor. Endocrinology 2008, 149(3):1075-1090. 10.1210/en.2007-0740, 18079201.
10. Kashyap AS, Hollier BG, Manton KJ, Satyamoorthy K, Leavesley DI, Upton Z. Insulin-like growth factor-I:vitronectin complex-induced changes in gene expression effect breast cell survival and migration. Endocrinology 2011, 152(4):1388-1401. 10.1210/en.2010-0897, 21303956.
11. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991, 88(6):1924-1932. 10.1172/JCI115516, 295768, 1721625.
12. Detre S, Saclani Jotti G, Dowsett M. A " quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995, 48(9):876-878. 10.1136/jcp.48.9.876, 502883, 7490328.
13. Ivaska J, Heino J. Cooperation between integrins and growth factor receptors in signaling and endocytosis. Annu Rev Cell Dev Biol 2011, 27:291-320. 10.1146/annurev-cellbio-092910-154017, 21663443.
14. Rosner M, Hanneder M, Freilinger A, HengstschlAger M. Nuclear/cytoplasmic localization of Akt activity in the cell cycle. Amino Acids 2007, 32(3):341-345. 10.1007/s00726-007-0509-0, 17357828.
15. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68(2):320-344. 10.1128/MMBR.68.2.320-344.2004, 419926, 15187187.
16. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119(6):1429-1437. 10.1172/JCI36183, 2689132, 19487819.
17. Destaing O, Planus E, Bouvard D, Oddou C, Badowski C, Bossy V, Raducanu A, Fourcade B, Albiges-Rizo C, Block MR. beta1A integrin is a master regulator of invadosome organization and function. Mol Biol Cell 2010, 21(23):4108-4119. 10.1091/mbc.E10-07-0580, 2993740, 20926684.
18. Mueller SC, Chen WT. Cellular invasion into matrix beads: localization of beta 1 integrins and fibronectin to the invadopodia. J Cell Sci 1991, 99(Pt 2):213-225.
19. Nakahara H, Mueller SC, Nomizu M, Yamada Y, Yeh Y, Chen WT. Activation of beta1 integrin signaling stimulates tyrosine phosphorylation of p190RhoGAP and membrane-protrusive activities at invadopodia. J Biol Chem 1998, 273(1):9-12. 10.1074/jbc.273.1.9, 9417037.
20. Leth-Larsen R, Lund R, Hansen HV, Laenkholm AV, Tarin D, Jensen ON, Ditzel HJ. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteomics 2009, 8(6):1436-1449. 10.1074/mcp.M800061-MCP200, 2690497, 19321434.
21. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ, Pavlidis N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002, 38(18):2362-2370. 10.1016/S0959-8049(02)00210-1, 12460779.
22. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141(1):52-67. 10.1016/j.cell.2010.03.015, 2862057, 20371345.
23. Galvez BG, Matias-Roman S, Yanez-Mo M, Sanchez-Madrid F, Arroyo AG. ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol 2002, 159(3):509-521. 10.1083/jcb.200205026, 2173082, 12427871.
24. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100(16):9482-9487. 10.1073/pnas.1633689100, 170944, 12874388.
25. Panetti TS, McKeown-Longo PJ. The alpha v beta 5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 1993, 268(16):11492-11495.
26. Roberts M, Barry S, Woods A, van der Sluijs P, Norman J. PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr Biol 2001, 11(18):1392-1402. 10.1016/S0960-9822(01)00442-0, 11566097.
27. Walsh LA, Damjanovski S. IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-beta1 resulting in epithelial to mesenchymal transition. Cell Commun Signal 2011, 9(1):10. 10.1186/1478-811X-9-10, 3104381, 21535875.
28. Sivakumar R, Koga H, Selvendiran K, Maeyama M, Ueno T, Sata M. Autocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transition. Int J Oncol 2009, 34(2):329-338.
29. Saji M, Vasko V, Kada F, Allbritton EH, Burman KD, Ringel MD. Akt1 contains a functional leucine-rich nuclear export sequence. Biochem Biophys Res Commun 2005, 332(1):167-173. 10.1016/j.bbrc.2005.04.109, 15896313.
30. Chuderland D, Konson A, Seger R. Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol Cell 2008, 31(6):850-861. 10.1016/j.molcel.2008.08.007, 18760948.
31. Adini I, Rabinovitz I, Sun JF, Prendergast GC, Benjamin LE. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev 2003, 17(21):2721-2732. 10.1101/gad.1134603, 280621, 14597666.
32. Macfarlane WM, Smith SB, James RF, Clifton AD, Doza YN, Cohen P, Docherty K. The p38/reactivating kinase mitogen-activated protein kinase cascade mediates the activation of the transcription factor insulin upstream factor 1 and insulin gene transcription by high glucose in pancreatic beta-cells. J Biol Chem 1997, 272(33):20936-20944. 10.1074/jbc.272.33.20936, 9252422.
33. Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 2010, 299(2):C189-C202. 10.1152/ajpcell.00347.2009, 20463170.
34. Baker SJ. PTEN enters the nuclear age. Cell 2007, 128(1):25-28. 10.1016/j.cell.2006.12.023, 17218252.
35. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006, 16(3):203-213. 10.1016/j.semcancer.2006.03.004, 16725345.
36. Hermeking H, Benzinger A. 14-3-3 proteins in cell cycle regulation. Semin Cancer Biol 2006, 16(3):183-192. 10.1016/j.semcancer.2006.03.002, 16697662.
37. Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R. Clinical significance of Stratifin, ERalpha and PR promoter methylation in tumor and serum DNA in Indian breast cancer patients. Clin Biochem 2010, 43(4-5):380-386.
38. Simooka H, Oyama T, Sano T, Horiguchi J, Nakajima T. Immunohistochemical analysis of 14-3-3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis. Pathol Int 2004, 54(8):595-602. 10.1111/j.1440-1827.2004.01668.x, 15260850.
39. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009, 69(8):3425-3432. 10.1158/0008-5472.CAN-08-2765, 2671640, 19318578.
40. Craparo A, Freund R, Gustafson TA. 14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner. J Biol Chem 1997, 272(17):11663-11669. 10.1074/jbc.272.17.11663, 9111084.
41. Yang H, Wen YY, Zhao R, Lin YL, Fournier K, Yang HY, Qiu Y, Diaz J, Laronga C, Lee MH. DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer. Cancer Res 2006, 66(6):3096-3105. 10.1158/0008-5472.CAN-05-3620, 16540659.
42. Chavez-Munoz C, Morse J, Kilani R, Ghahary A. Primary human keratinocytes externalize stratifin protein via exosomes. J Cell Biochem 2008, 104(6):2165-2173. 10.1002/jcb.21774, 18452139.
43. Ghahary A, Karimi-Busheri F, Marcoux Y, Li Y, Tredget EE, Taghi Kilani R, Li L, Zheng J, Karami A, Keller BO, Weinfeld M. Keratinocyte-releasable stratifin functions as a potent collagenase-stimulating factor in fibroblasts. J Invest Dermatol 2004, 122(5):1188-1197. 10.1111/j.0022-202X.2004.22519.x, 15140222.
44. Lam E, Kilani RT, Li Y, Tredget EE, Ghahary A. Stratifin-induced matrix metalloproteinase-1 in fibroblast is mediated by c-fos and p38 mitogen-activated protein kinase activation. J Invest Dermatol 2005, 125(2):230-238.
45. Ghaffari A, Li Y, Karami A, Ghaffari M, Tredget EE, Ghahary A. Fibroblast extracellular matrix gene expression in response to keratinocyte-releasable stratifin. J Cell Biochem 2006, 98(2):383-393. 10.1002/jcb.20782, 16440305.
46. Ivanova A, Liao SY, Lerman MI, Ivanov S, Stanbridge EJ. STRA13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker. J Med Genet 2005, 42(7):565-576. 10.1136/jmg.2004.029835, 1736099, 15994878.
47. Park J, Schwarzbauer JE. Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene 2014, 33(13):1649-1657. 10.1038/onc.2013.118, 23624917.
48. Petricevic B, Vrbanec D, Jakic-Razumovic J, Brcic I, Rabic D, Badovinac T, Ozimec E, Bali V. Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer. Med Oncol 2012, 29(2):486-494. 10.1007/s12032-011-9885-0, 21400218.
49. Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Protheroe AS, Howarth M, Macaulay VM. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res 2010, 70(16):6412-6419. 10.1158/0008-5472.CAN-10-0052, 2981028, 20710042.
50. Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 2009, 100(11):2028-2033. 10.1111/j.1349-7006.2009.01274.x, 19659610.